JNJ,PFE -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal8 hours ago

    [$$] Johnson & Johnson Drafted Into Fight Over Shareholder Lawsuits

    WASHINGTON—Johnson & Johnson Inc. is being drawn into a battle over how much freedom shareholders have to sue companies, in a bid by lawsuit opponents to force regulators to pick sides over investors’ access to the courts. Hal Scott, a Harvard University professor who represents a trust that owns J&J shares, filed a shareholder proposal with the company that would push shareholder disputes into private arbitration hearings, instead of federal court. J&J doesn’t want to bring the proposal up for a shareholder vote, and this week the health-care products company asked the Securities and Exchange Commission for permission to reject it.

  • A Closer Look at Biogen’s Gross Margin Trends
    Market Realist16 hours ago

    A Closer Look at Biogen’s Gross Margin Trends

    In 2018 and 2019, Biogen (BIIB) is expected to generate revenues of $13.31 billion and $13.66 billion, respectively, compared to $12.27 billion in 2017.

  • Zacks18 hours ago

    J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study

    J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.

  • Investing.com18 hours ago

    Stocks - Ciena Jumps in Premarket, Apple Gains, Tailored Brands Crashes

    Investing.com - Stocks in focus in premarket trade Thursday:

  • Motley Fool18 hours ago

    Top 10 Healthcare Stories of 2018

    New drugs, trial flops, M&A, and a little bit of everything else that happened in healthcare in 2018.

  • Zacks19 hours ago

    Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA

    Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.

  • Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?
    Zacks19 hours ago

    Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?

    Smart Beta ETF report for FLQL

  • Zacks20 hours ago

    Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug

    Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.

  • Zacks20 hours ago

    5 Dow Stocks Stand Tall Despite Index's Loss of 2018 Gains

    The Dow portfolio has depicted weak trends in 2018, thanks to concerns surrounding trade and interest rates. Nevertheless, strong U.S. economic fundamentals are likely to aid revival.

  • Are You Overlooking This High-Growth Industry During Corrections and Recessions?
    Motley Fool19 hours ago

    Are You Overlooking This High-Growth Industry During Corrections and Recessions?

    This industry could be a cure for your investing ills during even the most volatile times.

  • Understanding Abbott Laboratories’ Operational Performance
    Market Realist20 hours ago

    Understanding Abbott Laboratories’ Operational Performance

    In the latest quarter, Abbott Laboratories’ (ABT) selling, general, and administrative expenses rose YoY (year-over-year) to $2.38 billion from $2.11 billion due to its Alere acquisition and expenditure for expanding the company’s different businesses. Meanwhile, its R&D (research and development) expenses rose YoY to $574.0 million from $568.0 million due to the Alere acquisition and increased cardiovascular and neuromodulation spending. It is expected to have R&D expenses of $2.25 billion and $2.36 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $1. ...

  • Do Analysts See Any Upside for Abbott Stock?
    Market Realist20 hours ago

    Do Analysts See Any Upside for Abbott Stock?

    Of the 21 analysts covering Abbott Laboratories (ABT), 18 recommend “buy” or a higher rating, and three recommend “hold.” Their mean rating for Abbott stock is 1.76, and their target price is $79.44, implying a 10.6% upside for the stock based on its December 11 closing price of $71.84.

  • Abbott Laboratories’ Gross Margin Trends
    Market Realist20 hours ago

    Abbott Laboratories’ Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Abbott Laboratories (ABT) is expected to generate revenue of $30.66 billion and $32.21 billion, respectively, compared with revenue of $27.39 billion in fiscal 2017. Meanwhile, peers Biogen (BIIB), Johnson & Johnson (JNJ), and Pfizer (PFE) are expected to have revenue of $13.31 billion, $81.35 billion, and $53.59 billion, respectively, in fiscal 2018. Abbott’s cash per share is $4.20, while Biogen, Johnson & Johnson, and Pfizer have cash per share of $21.31, $7.20, and $2.90, respectively.

  • Zacks20 hours ago

    5 Dow Stocks Defying the Index's YTD Plunge

    The Dow 30 has been witnessing volatility in 2018 so far on account of investors' apprehension regarding investing in risky assets like equities.

  • Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
    Zacksyesterday

    Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

    In the latest trading session, Johnson & Johnson (JNJ) closed at $147.10, marking a +0.41% move from the previous day.

  • Why Arrowhead Pharmaceuticals Surged 11% Higher Today
    Motley Foolyesterday

    Why Arrowhead Pharmaceuticals Surged 11% Higher Today

    The company updated investors on its financial performance, and on its progress developing RNAi therapies.

  • Reutersyesterday

    J&J says its psoriasis drug superior to Novartis treatment in study

    Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study. After 48 weeks of therapy, 84.5 percent of the 1,048 participants treated with Tremfya showed 90 percent improvement in disease symptoms, as measured by the Psoriasis Area Severity Index, compared with 70 percent on Novartis's Cosentyx, J&J said.

  • InvestorPlace2 days ago

    5 Pharma Stocks That Could Cure Ailing Portfolios in 2019

    The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts. Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations.

  • Zacks2 days ago

    Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya

    The CHMP postpones the review timeline of Portola's (PTLA) Ondexxya (in the EU. Shares take a hit.

  • Zacks2 days ago

    Pfizer's (PFE) Shares Drop on Rating Downgrade by JP Morgan

    JP Morgan downgrades Pfizer (PFE) on assumptions that the market has discounted all growth factors for Pfizer.

  • Do Analysts See Any Upside for Regeneron Stock?
    Market Realist2 days ago

    Do Analysts See Any Upside for Regeneron Stock?

    Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.” Their mean rating for Regeneron stock is 2.58, and their target price is $426.05, implying a 12.8% upside for the stock based on its December 10 closing price of $377.59.

  • 5 Bargain Dividend Stocks to Buy Now
    Kiplinger2 days ago

    5 Bargain Dividend Stocks to Buy Now

    'Tis the season to go bargain hunting for stocks. It might not feel like it, what with the Dow Jones Industrial Average having kicked off December by shedding nearly 1,200 points, but now is the time to do some holiday shopping in the market, especially in dividend stocks. After all, as Warren Buffett likes to say, "Be greedy when others are fearful." And the way the market has been behaving lately, it's pretty clear that fear abounds. The general retreat in share prices means valuations are down and yields are up. (Dividend yields and stock prices move in opposite directions.) That has made several large-cap, high-quality dividend stocks look mighty tempting. The Standard & Poor's 500-stock index currently trades at 15 times expected earnings, according to Yardeni Research. To find bargains, we scoured the broad-market index for large companies that trade for less than 15 times projected earnings. At the same time, we limited our search to dependable dividend payers with yields of at least 3%. After taking long-term earnings growth forecasts and analysts' opinions into account, the following five names stood out as bargain dividend stocks to buy now. SEE ALSO: 19 Best Stocks to Buy for 2019

  • 3 Stocks That Could Help You Send Your Kids to College
    Motley Fool2 days ago

    3 Stocks That Could Help You Send Your Kids to College

    A college education isn't getting any cheaper. Pfizer, A.O. Smith, and Ceridian HCM could help put a diploma within reach.

  • Here's How to Survive a Stock Market Crash
    Motley Fool2 days ago

    Here's How to Survive a Stock Market Crash

    These tips can help you navigate a tumbling tape.